Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-1b)

Sponsor
Capital Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05909982
Collaborator
(none)
20
1
1
12
1.7

Study Details

Study Description

Brief Summary

Ischemic post-conditioning is a neuroprotective strategy attenuating reperfusion injury in animal stroke models. The investigators have conducted a 3 + 3 dose-escalation trial to demonstrate the safety and tolerability of ischemic post-conditioning incrementally for a longer duration of up to 5 min × 4 cycles in stroke patients undergoing mechanical thrombectomy. This study aims to assess the infarct volume after ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Mechanical thrombectomy combined with ischemic post-conditioning
Phase 1/Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Ischemic Post-conditioning on Infarct Volume in Patients With Acute Ischemic Stroke After Mechanical Thrombectomy
Actual Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ischemic post-conditioning group

Mechanical thrombectomy combined with ischemic post-conditioning

Procedure: Mechanical thrombectomy combined with ischemic post-conditioning
Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.

Outcome Measures

Primary Outcome Measures

  1. Infarct volume [72 hours after procedure]

    Infarct volume at 72 hours after procedure

Secondary Outcome Measures

  1. The progression of infarct volume [Baseline and 72 hours after procedure]

    Difference of infarct volume between baseline and 72 hours after procedure

  2. The proportion of functional independence at 90 days [90 days after procedure]

    The modified Rankin Scale (mRS) score of 0-2 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)

  3. The proportion of favorable outcome at 90 days [90 days after procedure]

    The mRS score of 0-3 at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)

  4. The distribution of the mRS score at 90 days [90 days after procedure]

    The distribution of the mRS score at 90 days after procedure; the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)

  5. National Institute of Health Stroke Scale (NIHSS) score [24 hours after procedure]

    NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits

  6. The proportion of early neurological improvement [24 hours after procedure]

    NIHSS 0-2 or ≥8 lower than baseline NIHSS score at 24 hours after procedure; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits

  7. NIHSS score at 7 days after procedure/discharge [7 days after procedure/discharge]

    NIHSS score at 7 days after procedure/discharge; the NIHSS ranges from 0 to 42, with higher scores indicating more severe neurologic deficits

  8. Recanalization rate [24 hours after procedure]

    Recanalization rate at 24 hours after procedure (mTICI ≥2b)

  9. Hemodynamic assessment [Within 24 hours after procedure]

    Hemodynamic assessment within 24 hours after procedure

Other Outcome Measures

  1. Safety outcome (mortality at 90 days) [90 days after procedure]

    90-day mortality

  2. Safety outcome (the proportion of symptomatic intracranial hemorrhage within 24 hours) [Within 24 hours after procedure]

    The proportion of symptomatic intracranial hemorrhage within 24 hours after procedure

  3. Safety outcome (the proportion of intracranial hemorrhage within 24 hours) [Within 24 hours after procedure]

    The proportion of intracranial hemorrhage within 24 hours after procedure

  4. Safety outcome (the proportion of malignant brain edema within 24 hours) [Within 24 hours after procedure]

    The proportion of malignant brain edema within 24 hours after procedure

  5. Procedure-related complications [During the procedure]

    Vascular perforation/rupture, vessel dissection, severe vasospasm, rupture of the balloon used for post-conditioning

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years;

  • Acute ischemic stroke within 24 hours from stroke onset (or from time last known well) to groin puncture;

  • Previous mRS ≤ 2;

  • Baseline NIHSS ≥ 6;

  • Baseline ASPECTS ≥ 6;

  • With an occlusion of unilateral middle cerebral artery M1 segment/distal intracranial carotid artery;

  • Successful recanalization (mTICI ≥ 2b) after thrombectomy confirmed by DSA;

  • Written informed consent provided by the patients or their legal relatives.

Exclusion Criteria:
  • Confirmed or clinically suspected cerebral vasculitis/fibromuscular dysplasia;

  • Difficulty in reaching the designated position of the balloon used for ischemic post-conditioning;

  • Stenting in the middle cerebral artery M1 segment/distal intracranial carotid artery during thrombectomy;

  • 2 times balloon dilations as rescue therapy due to angioplasty during thrombectomy;

  • Moderate/severe residual stenosis (≥ 50%) in the offending artery after thrombectomy;

  • Patients with contraindications to MRI;

  • Other conditions that the investigator considered inappropriate for inclusion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Huanhu Hospital Tianjin China 300350

Sponsors and Collaborators

  • Capital Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ji Xunming,MD,PhD, Professor, Capital Medical University
ClinicalTrials.gov Identifier:
NCT05909982
Other Study ID Numbers:
  • PROTECT-1b
First Posted:
Jun 18, 2023
Last Update Posted:
Jun 18, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2023